Loading…
Lucid Diagnostics Inc. is projected to rise to $1.08 by 2027, a +8% move from its current price of $1.00. LUCD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.9711 | $0.9995 | $1.03 | -0.05% |
| Jul 14 | $0.9591 | $0.999 | $1.04 | -0.10% |
| Jul 15 | $0.9498 | $0.9985 | $1.05 | -0.15% |
| Jul 16 | $0.9421 | $0.998 | $1.06 | -0.20% |
| Jul 17 | $0.9352 | $0.9975 | $1.06 | -0.25% |
| Jul 18 | $0.929 | $0.997 | $1.07 | -0.30% |
| Jul 19 | $0.9233 | $0.9965 | $1.08 | -0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9233 | $0.9965 | $1.08 | -0.35% |
| Week 2 | $0.8914 | $0.993 | $1.11 | -0.70% |
| Week 3 | $0.867 | $0.9895 | $1.13 | -1.05% |
| Week 4 | $0.8465 | $0.9861 | $1.15 | -1.39% |
| Week 5 | $0.8285 | $0.9826 | $1.17 | -1.74% |
| Week 6 | $0.8122 | $0.9792 | $1.18 | -2.08% |
| Week 7 | $0.7974 | $0.9757 | $1.19 | -2.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company operating in the United States. It focuses on patients with GERD who are at risk of developing esophageal precancer and cancer, primarily esophageal adenocarcinoma.
The flagship EsoGuard Esophageal DNA Test is performed on samples collected with the EsoCheck Esophageal Cell collection device, with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc. trades in the healthcare sector under the LUCD ticker. The current price is $0.9678 and the market cap is $184.63M, with a rank of 3868. These figures place the stock among smaller-cap healthcare names in the market.
The near-term outlook shows a neutral path, with the 2026 average price listed as $0.9678, a min of $0.947, and a max of $1.19, and a near-zero ROI of 0 with a Neutral sentiment.
Looking longer term, the forecast envisions steady upside over the next several years, with the 2030 average price at $1.21 and a 24.9 ROI, followed by continued growth to 2040 and 2050, where average prices reach $2.93 and $4.36 respectively and ROIs reach 202.3 and 350.3 while maintaining bullish sentiment.
A major floor 10.9% below — a decisive break under it would weaken the trend.
The nearest floor, 4.2% below — buyers have tended to step in here.
The nearest ceiling, 8.0% above — a clean break opens room to run.
A major ceiling 46.0% above — clearing it would confirm fresh momentum.
Key LUCD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LUCD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.01 | Sell | $1.01 | Sell |
| MA 10 | $1.04 | Sell | $1.02 | Sell |
| MA 20 | $1.03 | Sell | $1.03 | Sell |
| MA 50 | $1.03 | Sell | $1.05 | Sell |
| MA 100 | $1.16 | Sell | $1.10 | Sell |
| MA 200 | $1.15 | Sell | $1.13 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.95 | Neutral |
| Stoch RSI (14) | 30.00 | Neutral |
| CCI (20) | -55.47 | Neutral |
| Williams %R (14) | -71.43 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -2.91 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 28.57 | Neutral |
| TRIX (15) | 0.01 | Buy |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 36.27 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 0.97 | Buy |
| ADX (14) | 10.32 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture shows BEARISH sentiment. The RSI(14) is 40, and the 50-day simple moving average (SMA50) is $1.03 while the 200-day simple moving average (SMA200) is $1.15, highlighting a modestly negative tilt versus longer-term levels.
Immediate support is at $0.958 and resistance at $1.11, framing a tight near-term range. The 30-day range runs from $0.7926 to $1.18, signaling limited upside pressure in the very near term. The annualized volatility stands around 60%, underscoring a higher-than-average swing risk in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.947 | $1.00 | $1.23 | 0% | Neutral | |
| $0.8591 | $1.08 | $1.45 | +8% | Neutral | |
| $0.877 | $1.14 | $1.59 | +14% | Neutral | |
| $0.8218 | $1.10 | $1.57 | +10% | Neutral | |
| $0.9347 | $1.27 | $1.87 | +27% | Bullish | |
| $1.11 | $1.54 | $2.32 | +54% | Bullish | |
| $1.23 | $1.74 | $2.67 | +74% | Bullish | |
| $1.28 | $1.85 | $2.89 | +85% | Bullish | |
| $1.28 | $1.88 | $2.98 | +88% | Bullish | |
| $1.34 | $1.99 | $3.21 | +99% | Bullish | |
| $1.95 | $3.12 | $5.37 | +212% | Bullish | |
| $2.61 | $4.73 | $8.92 | +373% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.947 | $1.00 | $1.21 | +0.00% |
| August 2026 | $0.8371 | $0.9895 | $1.20 | -1.05% |
| September 2026 | $0.8022 | $0.9553 | $1.17 | -3.45% |
| October 2026 | $0.8078 | $0.968 | $1.20 | +1.33% |
| November 2026 | $0.8192 | $0.9871 | $1.24 | +1.97% |
| December 2026 | $0.8035 | $0.973 | $1.23 | -1.42% |
Click any year to see its month-by-month LUCD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Lucid Diagnostics Inc.'s 2026 outlook centres on $1.00, within a $0.947 to $1.23 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, LUCD could reach as high as $1.45, with a base case around $1.08 and support toward $0.8591 — roughly +8% from $1.00. Price action looks broadly range-bound.
Expect LUCD to range from $0.877 to $1.59 through 2028. The $1.14 average target implies a +14% move from current prices. That is up +5% on the projected 2027 average. A consolidation phase looks the most probable path here.
The LUCD price prediction for 2029 points to an average of $1.10 (low $0.8218, high $1.57) — a potential gain of +10% on today's $1.00. Price action looks broadly range-bound.
In 2030, LUCD is projected to trade between $0.9347 and $1.87, averaging $1.27 — a potential gain of +27% from today's $1.00. That is up +16% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Lucid Diagnostics Inc.'s 2031 outlook centres on $1.54, within a $1.11 to $2.32 range. That is up +21% on the projected 2030 average. That marks a +54% change versus current levels. Momentum favours further upside here.
By 2032, LUCD could reach as high as $2.67, with a base case around $1.74 and support toward $1.23 — roughly +74% from $1.00. Buyers look set to stay in control over this stretch.
Expect LUCD to range from $1.28 to $2.89 through 2033. The $1.85 average target implies a +85% move from current prices. That is up +6% on the projected 2032 average. Momentum favours further upside here.
The LUCD price prediction for 2034 points to an average of $1.88 (low $1.28, high $2.98) — a potential gain of +88% on today's $1.00. Buyers look set to stay in control over this stretch.
In 2035, LUCD is projected to trade between $1.34 and $3.21, averaging $1.99 — a potential gain of +99% from today's $1.00. That is up +6% on the projected 2034 average. Momentum favours further upside here.
Lucid Diagnostics Inc.'s 2040 outlook centres on $3.12, within a $1.95 to $5.37 range. That is up +57% on the projected 2035 average. That marks a +212% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, LUCD could reach as high as $8.92, with a base case around $4.73 and support toward $2.61 — roughly +373% from $1.00. Momentum favours further upside here.
Investing $1,000 in LUCD today (≈ 1,000 LUCD) could be worth
$4,725.21
+$3,725.21 (+373%) by 2050 · US Dollar
Based on the average projected LUCD price of $4.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LUCDwould be worth at today's price.
$1,000 invested in LUCD on Jul 10, 2025 (≈ 847.457665 LUCD) would be worth
$847.46
-$152.54 (-15.3%) today · 0.85× · US Dollar
Based on a LUCD entry price of $1.18 vs. today's $1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.07 | $934.58 | -6.5% |
| 1 month ago | $1.01 | $990.1 | -1.0% |
| 3 months ago | $1.15 | $869.57 | -13.0% |
| 6 months ago | $1.19 | $840.34 | -16.0% |
| 1 year ago | $1.18 | $847.46 | -15.3% |
| All time (4.7y) ago | $11.76 | $85.03 | -91.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LUCD forecast.
Our base-case forecast reaches $2.00 around 2040.
Implied market cap at $2.00: $381.54M
The multi-year forecast shows a clear bullish shift beginning around 2030. In 2030 the average price is projected at $1.21 with a 24.9 ROI and a bullish sentiment. The sequence continues with rising averages and higher ROIs: 2031 avg $1.46 (51), 2032 avg $1.64 (69.6), 2033 avg $1.75 (81.3), 2034 avg $1.77 (83.1), 2035 avg $1.86 (92.5).
By 2040, the average price is projected at $2.93 with a 202.3 ROI and a bullish sentiment, and by 2050 the average rises to $4.36 with a 350.3 ROI. The 2040 max reaches $5.11 and the 2050 max reaches $8.38, indicating substantial potential upside over the longer horizon while acknowledging that these are estimates, not guarantees. Risks and uncertainty are inherent in any forecast.
Tap a question to reveal the answer.
In 2030, the forecast shows an avg price of $1.21 with a ROI of 24.9 and a bullish sentiment; the min is $0.8787 and the max is $1.80.
The forecast indicates a bullish path from 2030 onward, with 2030 avg $1.21 and 24.9 ROI, 2040 avg $2.93 with 202.3 ROI, and 2050 avg $4.36 with 350.3 ROI, though near-term figures (2026) show a neutral stance and minimal ROI.
Yes—the forecast shows a 2040 max of $5.11, which is around $5 given the projected range.
Current price is $0.9678 and market cap is $184.63M.
The 30-day picture is BEARISH with RSI(14) at 40, SMA50 at $1.03, SMA200 at $1.15, support at $0.958, resistance at $1.11, and a 30-day range of $0.7926–$1.18; annualized volatility is 60%.
Lucid Diagnostics Inc. Community Discussion
0Share your Lucid Diagnostics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.